NASDAQ
ALGS

Aligos Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Aligos Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.8
Today's High:
$0.86
Open Price:
$0.835
52W Low:
$0.84
52W High:
$2.99
Prev. Close:
$0.835
Volume:
12421

Company Statistics

Market Cap.:
$62.94 million
Book Value:
2.85
Revenue TTM:
$10.74 million
Operating Margin TTM:
-1051%
Gross Profit TTM:
$-99794000
Profit Margin:
0%
Return on Assets TTM:
-33.02%
Return on Equity TTM:
-66%

Company Profile

Aligos Therapeutics Inc had its IPO on 2020-10-16 under the ticker symbol ALGS.

The company operates in the Healthcare sector and Biotechnology industry. Aligos Therapeutics Inc has a staff strength of 89 employees.

Stock update

Shares of Aligos Therapeutics Inc opened at $0.84 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.8 - $0.86, and closed at $0.8.

This is a -4.19% slip from the previous day's closing price.

A total volume of 12,421 shares were traded at the close of the day’s session.

In the last one week, shares of Aligos Therapeutics Inc have slipped by -8.05%.

Aligos Therapeutics Inc's Key Ratios

Aligos Therapeutics Inc has a market cap of $62.94 million, indicating a price to book ratio of 0.3509 and a price to sales ratio of 3.7883.

In the last 12-months Aligos Therapeutics Inc’s revenue was $10.74 million with a gross profit of $-99794000 and an EBITDA of $-110334000. The EBITDA ratio measures Aligos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aligos Therapeutics Inc’s operating margin was -1051% while its return on assets stood at -33.02% with a return of equity of -66%.

In Q3, Aligos Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 167.1%.

Aligos Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aligos Therapeutics Inc’s profitability.

Aligos Therapeutics Inc stock is trading at a EV to sales ratio of 69.4811 and a EV to EBITDA ratio of 0.7928. Its price to sales ratio in the trailing 12-months stood at 3.7883.

Aligos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$164.07 million
Total Liabilities
$30.54 million
Operating Cash Flow
$32.48 million
Capital Expenditure
$3000
Dividend Payout Ratio
0%

Aligos Therapeutics Inc ended 2024 with $164.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $164.07 million while shareholder equity stood at $122.01 million.

Aligos Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $30.54 million in other current liabilities, 4000.00 in common stock, $-377232000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $86.44 million and cash and short-term investments were $142.30 million. The company’s total short-term debt was $3,207,000 while long-term debt stood at $0.

Aligos Therapeutics Inc’s total current assets stands at $150.09 million while long-term investments were $0.00 and short-term investments were $55.86 million. Its net receivables were $0 compared to accounts payable of $2.93 million and inventory worth $0.

In 2024, Aligos Therapeutics Inc's operating cash flow was $32.48 million while its capital expenditure stood at $3000.

Comparatively, Aligos Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.8
52-Week High
$2.99
52-Week Low
$0.84
Analyst Target Price
$3.64

Aligos Therapeutics Inc stock is currently trading at $0.8 per share. It touched a 52-week high of $2.99 and a 52-week low of $2.99. Analysts tracking the stock have a 12-month average target price of $3.64.

Its 50-day moving average was $0.92 and 200-day moving average was $1.16 The short ratio stood at 1.55 indicating a short percent outstanding of 0%.

Around 1534.7% of the company’s stock are held by insiders while 6198.4% are held by institutions.

Frequently Asked Questions About Aligos Therapeutics Inc

The stock symbol (also called stock or share ticker) of Aligos Therapeutics Inc is ALGS

The IPO of Aligos Therapeutics Inc took place on 2020-10-16

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$7.8
-0.2
-2.5%
$216.4
-6.9
-3.09%
$96.69
0.32
+0.33%
$164.35
-14.35
-8.03%
$0.09
-0.01
-8.87%
$72.55
2.75
+3.94%
$5.01
-0.16
-3.09%
$4503.25
-177.45
-3.79%
$36.34
1.73
+5%
$12.87
-0.32
-2.43%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Address

One Corporate Drive, South San Francisco, CA, United States, 94080